Incidence of intussusception among infants in a large commercially insured population in the United States
- PMID: 22173141
- DOI: 10.1097/INF.0b013e31824213b1
Incidence of intussusception among infants in a large commercially insured population in the United States
Abstract
Background: To estimate the incidence of intussusception among infants treated in inpatient and emergency department settings during the period preceding the US launch of second-generation rotavirus vaccines.
Methods: From a large US health insurance claims database, we sampled 100,000 infants aged 1 to 3 months at first diphtheria-tetanus-acellular pertussis vaccination between 2001 and 2005. Potential intussusception cases were identified on the basis of claims and were confirmed by medical record review. Incidence rates (IRs) and 95% confidence intervals (CIs) were estimated based on follow-up from first diphtheria-tetanus-acellular pertussis dose to up to 1 year of age, and within 21, 30, and 60 days after each dose.
Results: The IR of intussusception in the first year of life was 0.33/1000 person-years based on 22 confirmed cases (95% CI: 0.21-0.50/1000 person-years). The age-specific incidence peaked among infants aged 5 months (IR: 0.82/1000 person-years; 95% CI: 0.30-1.78/1000 person-years). During the 21, 30, and 60 days following any dose, the incidence per 1000 person-years was 0.27, 0.24, and 0.33, respectively.
Conclusion: The rates described in this study can serve as a benchmark for comparison with incidences observed after the introduction of the second-generation rotavirus vaccines.
Similar articles
-
Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine.Pediatr Infect Dis J. 2012 Mar;31(3):292-6. doi: 10.1097/INF.0b013e3182421390. Pediatr Infect Dis J. 2012. PMID: 22173146 Clinical Trial.
-
Rotavirus vaccination and intussusception: can we decrease temporally associated background cases of intussusception by restricting the vaccination schedule?Pediatrics. 2006 Aug;118(2):e258-64. doi: 10.1542/peds.2005-2874. Pediatrics. 2006. PMID: 16882770
-
Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.Pediatrics. 2006 Sep;118(3):978-84. doi: 10.1542/peds.2005-2746. Pediatrics. 2006. PMID: 16950988
-
Rotavirus live, oral, pentavalent vaccine.Clin Ther. 2007 Dec;29(12):2724-37. doi: 10.1016/j.clinthera.2007.12.018. Clin Ther. 2007. PMID: 18201590 Review.
-
Rotavirus vaccines and intussusception risk.Curr Opin Gastroenterol. 2005 Jan;21(1):20-5. Curr Opin Gastroenterol. 2005. PMID: 15687880 Review.
Cited by
-
Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception.Drug Saf. 2022 Feb;45(2):155-168. doi: 10.1007/s40264-021-01141-4. Epub 2022 Jan 11. Drug Saf. 2022. PMID: 35015268 Free PMC article.
-
Pediatric intussusception: innovative reduction.Quant Imaging Med Surg. 2024 Oct 1;14(10):7736-7739. doi: 10.21037/qims-24-668. Epub 2024 Sep 9. Quant Imaging Med Surg. 2024. PMID: 39429590 Free PMC article. No abstract available.
-
Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries.Hum Vaccin Immunother. 2016 Oct 2;12(10):2580-2589. doi: 10.1080/21645515.2016.1197452. Epub 2016 Jun 20. Hum Vaccin Immunother. 2016. PMID: 27322835 Free PMC article. Review.
-
Management for intussusception in children.Cochrane Database Syst Rev. 2017 Jun 1;6(6):CD006476. doi: 10.1002/14651858.CD006476.pub3. Cochrane Database Syst Rev. 2017. PMID: 28567798 Free PMC article.
-
Assessment of a Claims-Based ICD-9 and ICD-10 Medication-Related Osteonecrosis of the Jaw Algorithm in the United States.Clin Epidemiol. 2021 Oct 28;13:1019-1026. doi: 10.2147/CLEP.S325080. eCollection 2021. Clin Epidemiol. 2021. PMID: 34737646 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources